Following the International Myeloma Working Group criteria, we usually check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Following the International Myeloma Working Group criteria, we usually check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Transcript
At what point after treatment should patients with multiple myeloma have an MRD assessment?
Well, usually we check for minimal residual disease when the patient has reached a complete remission or is very close to complete remission. So, right now the International Myeloma Working Group criteria say that you would check for this when the patients have complete remission, and you can do this by flow cytometry or sequencing—whatever is available at your institution. You don't have to choose 1 over the other. You do have to be aware of the sensitivity of the assay–there are different sensitivities depending on the number of cells that you analyze from the bone marrow. So, that's basically what you need to know.
Now if the patient is MRD negative, you may want to recheck that. There is a category in the response which is sustained MRD negativity, which does say that at 1-year intervals, the patient remains negative. So, if you want to do the assessment once the patient has reached the complete remission, and if the patient is negative, you want to check again maybe in a year. If the patient is still negative after 1 or 2 years, you can say that the patient is in the sustained minimal residual disease negative zone category in the response criteria for multiple myeloma.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen